EQT agrees to all‑cash takeover of Qiagen at €46.50 per share

Swedish private‑equity firm EQT announced a binding offer of €46.50 per share for Qiagen, valuing the company at about €9.6 billion in equity and roughly €10.8 billion including debt. Qiagen’s supervisory and managing boards unanimously approved the transaction, which will be funded by equity and debt and is expected to close in mid‑2027. The offer represents a premium of roughly 40 % over the July 8, 2026 closing price of €33.15, and the shares rose about 0.7 % after the announcement.

The cash offer provides shareholders with an immediate premium payout and will result in Qiagen’s delisting from the NYSE and Frankfurt exchanges, changing the company’s capital structure and liquidity profile. The board’s approval signals that the transaction is likely to proceed, subject to regulatory clearance.

Sources